麦克奥迪(300341) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥359,515,780.05, representing a 24.09% increase compared to ¥289,716,975.56 in the same period last year[3] - Net profit attributable to shareholders was ¥45,610,282.01, up 29.71% from ¥35,164,208.37 year-on-year[3] - Basic and diluted earnings per share increased by 29.75% to ¥0.0894 from ¥0.0689 in the same period last year[3] - The total operating revenue for Q1 2022 was CNY 359,515,780.05, representing an increase of 24.1% compared to CNY 289,716,975.56 in the same period last year[15] - The net profit for Q1 2022 reached CNY 47,191,169.22, a 26.9% increase from CNY 37,206,452.32 in Q1 2021[16] - The operating profit for Q1 2022 was CNY 58,774,362.85, compared to CNY 46,618,308.49 in the previous year, marking a growth of 25.9%[15] Cash Flow - The net cash flow from operating activities decreased by 72.51% to ¥14,251,925.13, down from ¥51,846,277.69 in the previous year[3] - The cash flow from operating activities for Q1 2022 was CNY 14,251,925.13, a decrease of 72.5% from CNY 51,846,277.69 in Q1 2021[18] - The net cash flow from investment activities was 3,163,795.93 CNY, compared to a negative cash flow of -20,634,780.38 CNY in the previous year[20] - The cash flow from financing activities resulted in a net outflow of -41,107,542.52 CNY, compared to -11,846,275.79 CNY in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,894,750,084.78, a 1.78% increase from ¥1,861,536,925.53 at the end of the previous year[3] - Total liabilities amounted to CNY 1,361,970,870.49, with current liabilities including accounts payable at CNY 151,641,669.50[12] - The total liabilities as of Q1 2022 were CNY 466,767,628.59, a slight decrease from CNY 483,440,978.67 in the previous year[14] - The company’s equity position remains strong with total equity reflecting the growth in assets and liabilities management[12] Shareholder Information - The company reported a decrease in financial expenses to CNY 2,706,932.75 from CNY 5,537,831.65 in the previous year, indicating improved cost management[15] - The top shareholder, Beijing Yizhuang Investment Holding Co., Ltd., holds 29.99% of shares, indicating significant ownership concentration[8] Operational Efficiency - The balance of accounts receivable decreased by 44.42% to ¥8,536,600 from the beginning of the period, primarily due to the use of commercial acceptance bills for payments[6] - Prepayments increased by 102.35% to ¥21,145,500, mainly due to an increase in prepayments in the medical sector[6] - The company is actively managing its receivables and inventory to optimize cash flow and operational efficiency[12] - The company experienced a significant increase in research and development expenses, totaling CNY 15,361,562.74, compared to CNY 14,839,885.57 in Q1 2021, reflecting a focus on innovation[15] Cash Reserves - Cash and cash equivalents decreased to CNY 481,328,478.98 from CNY 530,642,545.42, indicating a reduction in cash reserves[11] - The ending balance of cash and cash equivalents was 479,640,726.50 CNY, down from 486,028,671.73 CNY year-over-year[20]